HomeHealthcare & Life SciencesPharmaceuticals Charles Bonnet Syndrome Market

Europe Charles Bonnet Syndrome Market Size & Outlook, 2026-2034


Europe Charles Bonnet Syndrome Market Insights

  • Reed Intelligence analysis indicates that the Europe Charles Bonnet Syndrome Market size, which was USD 116.5 Million in 2025, is projected to attain USD 240 Million by 2034.
  • The market is expected to register a CAGR of 8.28% over the period 2026–2034.
  • In 2025, Pharmacological Therapy emerged as the dominant By Treatment Type based on market size.
  • Pharmacological Therapy is projected to register the fastest growth, positioning it as the most attractive By Treatment Type segment over the forecast horizon.

Other Key Findings


  • The global Charles Bonnet Syndrome Market size saw Europe holding a share of 37.58% in 2025.
  • United States is forecasted to account for the leading share of the global market by 2034.
  • In Europe, Russia is forecasted to be the fastest-expanding market, projected to reach USD 19.78 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 116.5 Million
Market Size In 2034 USD 240 Million
Largest segment Pharmacological Therapy
Units Revenue in USD Million
CAGR 8.28% (2026-2034)
Segmnetation Covered
Europe
  1. Germany
  2. United Kingdom
  3. France
  4. Italy
  5. Spain
  6. Russia
  7. Nordic
  8. Benelux
By Treatment Type
  1. Pharmacological Therapy
  2. Digital Therapeutics
  3. Behavioral Therapy
By Diagnosis Type
  1. Clinical Diagnosis
  2. AI-Assisted Diagnosis
By End-Use
  1. Hospitals
  2. Clinics
  3. Home Care Settings
By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports